RU2002130448A - PHARMACEUTICAL COMPOSITION HAVING A THROMBOLYTIC AND FIBRINOLYTIC ACTION - Google Patents
PHARMACEUTICAL COMPOSITION HAVING A THROMBOLYTIC AND FIBRINOLYTIC ACTIONInfo
- Publication number
- RU2002130448A RU2002130448A RU2002130448/15A RU2002130448A RU2002130448A RU 2002130448 A RU2002130448 A RU 2002130448A RU 2002130448/15 A RU2002130448/15 A RU 2002130448/15A RU 2002130448 A RU2002130448 A RU 2002130448A RU 2002130448 A RU2002130448 A RU 2002130448A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- thrombolytic
- maput22
- dextran
- pharmaceutical composition
- Prior art date
Links
- 230000003480 fibrinolytic Effects 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 230000002537 thrombolytic Effects 0.000 title claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 4
- 229920002307 Dextran Polymers 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 229940088598 Enzyme Drugs 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2002130448/14A RU2216348C1 (en) | 2002-11-14 | 2002-11-14 | Pharmaceutical composition eliciting thrombolytic and fibrinolytic effect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2002130448/14A RU2216348C1 (en) | 2002-11-14 | 2002-11-14 | Pharmaceutical composition eliciting thrombolytic and fibrinolytic effect |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2216348C1 RU2216348C1 (en) | 2003-11-20 |
RU2002130448A true RU2002130448A (en) | 2004-06-10 |
Family
ID=32028282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002130448/14A RU2216348C1 (en) | 2002-11-14 | 2002-11-14 | Pharmaceutical composition eliciting thrombolytic and fibrinolytic effect |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2216348C1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2335167B1 (en) * | 2007-02-26 | 2011-01-24 | Proyecto De Biomedicina Cima, S.L. | USE OF METALOPROTEINASE MATRIX-10 (MMP10) FOR THROMBOLITIC TREATMENTS. |
RU2448156C1 (en) * | 2011-03-17 | 2012-04-20 | Эспосито Трейдинг Лтд | Method of producing lyophilised substance |
RU2765043C1 (en) * | 2020-12-02 | 2022-01-25 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) | Two-component pharmaceutical composition having fibrinolytic effect |
-
2002
- 2002-11-14 RU RU2002130448/14A patent/RU2216348C1/en active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1232251B1 (en) | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin | |
Lijnen et al. | Fibrinolytic agents: mechanisms of activity and pharmacology | |
US6964764B2 (en) | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin | |
HU185223B (en) | Process for preparing an enzymatic derivative containing a binary complex of streptokynase and plasminogen | |
EP0217379A2 (en) | Thrombolytic composition and a process for production thereof | |
CN1122573A (en) | Oxygen-reduced aqueous solution of factor VIII | |
US4980165A (en) | Pharmaceutical formulations of plasminogen activator proteins | |
JPH0680015B2 (en) | Pharmaceutical composition | |
KR890000103A (en) | Method for preparing high concentration solution of protein with tissue plasminogen activator (t-PA) activity, solution containing protein with t-PA activity, and use of solution in human and veterinary medicine | |
AU623347B2 (en) | Thrombolytic agent | |
US6969515B2 (en) | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin | |
EP1459738B1 (en) | Pharmaceutical composition having thrombolytic, anti-inflammatory and cytoprotective properties | |
RU2002130448A (en) | PHARMACEUTICAL COMPOSITION HAVING A THROMBOLYTIC AND FIBRINOLYTIC ACTION | |
Lijnen et al. | Mechanisms of plasminogen activation by mammalian plasminogen activators | |
HU216793B (en) | Process for producing pharmaceutical compositions containing nonglycozylized k2p pro t-pa | |
US6759042B2 (en) | Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent | |
WO2004028457A3 (en) | PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY | |
Goldfarb et al. | Degradation of glycoprotein and collagenous components of the basement membrane: studies with urokinase-type plasminogen activator, α-thrombin, and plasmin | |
Sawa et al. | Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-α converting enzyme (TACE) | |
PT98823A (en) | METHOD FOR PREPARING A HYBRID PLASMINOGEN ACTIVATOR | |
JPS61236730A (en) | Medicine containing plasminogen activator | |
WO2001080811A2 (en) | Mmp-2 propeptide for use as antiangiogenic or antitumor agent | |
Thomson | New thrombolytic drugs | |
JP2005532377A (en) | A novel combination formulation based on magnesium salt and fibrinolytic agent | |
DK163175B (en) | SYNERGISTIC PHARMACEUTICAL COMBINATION PREPARATION OF PLASMINOGEN ACTIVATOR, T-PA, AND OXYPURINOL |